AI heart failure trial pulled before starting

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provide written and dated informed consent for participation prior to trial admission, 2. Age ≥18 years, female or male 3. Diagnosis of heart failure\* either before discharge of a heart failure hospital admission or in the outpatient setting, 4. Symptomatic, defined as NYHA class II - IV, 5. LVEF \< 50% measured in the last 12 months (using any modality), with no occurrence of HF event(s) since that measurement) and 6. Those not previously treated with evidence-based therapies or sub-optimally treated with GDMT defined as; • Not treated with one of the foundational four\*\* HF medication unless absolute contraindication or documented intolerance * Definition of heart failure according to the most recent Heart Failure Guidelines of the European Society of Cardiology * Foundational four heart failure medication: BBs, ARNi, MRAs and SGLT2i. NB. This does not include ACE and ARBs these are permitted. Exclusion Criteria: 1. Inability to understand and sign informed consent, 2. Scheduled or on renal replacement therapy, 3. Clearly documented intolerance to BBs, ARNI, SGLT2i or MRAs 4. Diagnosis of acute myocarditis or (non)obstructive hypertrophic cardiomyopathy, 5. The presence of a mechanical assist device, 6. Scheduled for mechanical assist device or heart transplant, 7. Acute coronary syndrome (ACS) in the past 3 months or current angina pectoris ≥class III, 8. Requiring valvular surgery or revascularization in the upcoming 3 months or revascularization within the past 3 months, 9. Anticipated need for surgery or any cardiovascular intervention, except implantable cardioverter defibrillator and/or cardiac resynchronization therapy, within 4 weeks, 10. Other non-cardiac conditions with limited life expectancy (≤ duration of the trial/ 1 year), 11. Participation in another (intervention) clinical trial (registry studies not included) until the onsite EoS visit (V5) at 9 months has been completed. 12. Women who are pregnant, breastfeeding or may be considering pregnancy during the study duration.